middle.news
How Cambium Bio’s $2.12M Raise Fuels Elate Ocular® Phase 3 Launch
4:35am on Saturday 30th of August, 2025 AEST
•
Biotechnology
Read Story
How Cambium Bio’s $2.12M Raise Fuels Elate Ocular® Phase 3 Launch
4:35am on Saturday 30th of August, 2025 AEST
Key Points
FY25 net loss of $3.84 million amid increased royalty revenue
FDA Fast Track designation and Phase 3 protocol approvals secured
Ethics approvals obtained in Australia and US for trial commencement
Fully subscribed $2.12 million placement completed post year-end
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE